Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-12-17

Clinical Trial Update: Trial of Rifaximin in Probable Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of rifaximin in probable Alzheimer's disease has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rifaximin (rifaximin)

Snippet

Sponsor: Duke University | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2021-12-17